breast tissue News
-
IMPACT Lourdes awards grant for MarginProbe
IMPACT Lourdes, the women’s philanthropy group that supports the Mercy Health Foundation Lourdes, has awarded its annual grant to benefit Mercy Health — Lourdes Hospital. IMPACT Lourdes members voted to award $30,000 to purchase the MarginProbe system, equipment that assists in detecting cancerous breast tissue. With MarginProbe, surgeons can assess breast tissue in the operating ...
-
Showcase
Northern Arizona, Verde Valley MC Highlights VeraForm; Importance Marking Breast Surgical Site
As a patient facing breast cancer surgery, you should know that precise "marking" of your cancer surgical site is an important part of your treatment. A marker is a device inserted at the surgical site. Precision in marking helps make sure you retain as much normal breast tissue as possible with the surgery. This ultimately leads to best overall post-surgical care by your wellness team. A new ...
-
Showcase
Koning Ends the Year with $2.6M Republic Raise
NORCROSS, Ga., Feb. 1, 2022 /PRNewswire/ -- Koning, a growing medical device startup company based outside Atlanta, had a successful conclusion to 2021. The company recently finished their first Republic crowdfunding campaign, exceeding capital targets, and raising over $2.6M in only 5 months. Koning's FDA breast screening trial is also underway with participating clinics in Daytona Beach, FL and ...
-
Showcase
Koning Begins FDA Clinical Screening Trial in Daytona Beach, Florida
DAYTONA BEACH, Fla., Nov. 1, 2021 /PRNewswire/ -- Koning begins an FDA screening trial this month for their no-compression, Isotropic, 3-dimensional breast imaging device. The company received FDA PMA approval for commercial, diagnostic use in 2017. Since then, the Koning Breast CT (KBCT) has been installed in clinics and universities in the US and globally. "This FDA screening trial is a major ...
-
Koning Goes Live on Investment Platform, Republic, With More Milestones to Come
Koning’s Series C fundraise is now available to both accredited and everyday investors via two leading tech investment websites. Atlanta, GA: After launching on Revere on Monday, Koning Corporation has launched a second fundraising campaign on the investment platform Republic. “We’re very excited to be both on Republic and Revere. This is our official first public solicitation ...
-
QView Medical in Support of Breast Cancer Awareness Month Joins the Initiative of AmIDense.com
QView Medical is the only FDA AI Ultrasound Technology approved for breast screening. But now, we are moving beyond the clinical suite. QView is joining women in the initiative around Breast Cancer with the launch of AmIDense.com and the supporting #AmIDense. Let's START the conversation around Breast Density. The 2021 American Cancer Society's estimate is 280,000 women will be diagnosed with ...
-
Koning Republic Campaign Reaches New Milestones
Atlanta, GA: A month into Koning’s Republic fundraising campaign, the company has already passed a quarter of a million dollars of investments from 740 investors. “We’re proud of the progress we’ve made on the campaign so far and we’re confident that this positive trajectory will continue”, says Koning’s US CEO, Lutao Ning. “It goes to show how ...
-
Koning Announces Partnership to Get Ten Breast CT Devices Installed in Southeast Asia in Time For Breast Cancer Awareness Month
HONG KONG, Oct. 8, 2021 /PRNewswire/ -- Koning Corporation has been working to get more Koning Breast CT (KBCT) into clinics not only throughout the US, but also around the world. Within the past week, the company has entered into a partnership with Chesa Industries LTD with the intention of putting ten KBCT into clinics across Southeast Asia. “This partnership will allow many more women ...
-
Koning Selected as Finalist to Present at Women’s Health Innovation Summit
Boston, MA: Koning has been selected as a finalist to present at the Women’s Health Innovation Summit on September 14, 2021. Of over 100 applicants, Koning is one of only ten companies that has been chosen and will showcase the Koning Breast CT - a technology that will change millions of women’s lives around the world through no compression, low dose, and true 3D imaging. ...
-
QView Medical maintains leadership position in AI-powered breast cancer screening technology through alliance with GE Healthcare
QView Medical, a breast cancer detection pioneer and maker of the FDA-approved artificial intelligence (AI) software system for breast cancer screening, and GE Healthcare today announced that QView's QVCAD software can be launched on GE Healthcare's Invenia™ ABUS 2.0 (Automated Breast Ultrasound), which has an open platform technology that allows the integration of third-party AI tools for ...
-
Koning Goes Live on Investment Platform, Revere
Koning’s Series C fundraise is now available to accredited investors via a leading tech investment website, Revere Atlanta, GA: Koning Corporation is now live on the investment platform, Revere, which specializes in raising funds for scalable, high-value technology companies. “We’re excited to bring this opportunity to investors who believe, like we do, in the ...
-
Koning Goes Live on Investment Platform, Revere
Koning Corporation is now live on the investment platform, Revere, which specializes in raising funds for scalable, high-value technology companies. “We’re excited to bring this opportunity to investors who believe, like we do, in the advancement of women’s health through better breast imaging techniques,” says Koning’s US CEO, Lutao Ning. “We believe that ...
-
AMA recognizes Dedicated Breast CT by assigning 6 CPT Codes
On June 15th, 2020, the American Medical Association (AMA) granted 6 Category III CPT codes for the FDA PMA cleared dedicated breast CT imaging procedure. The newly assigned CPT codes in addition to the previous FDA PMA clearance process, formally introduces access to this new and advanced modality on January 1, 2021. The AMA technical subcommittee, comprised of prominent members of the ...
-
AI ‘Fingerprinting’ Fights Back Against Hard-to-Detect Cancers
Hard-to-detect cancers like glioblastoma can have survival rates in the single-digit percentages and require elaborate techniques to detect, treat, and monitor. Reveal Surgical is working on changing that reality through its new, AI-based Sentry technology, which leverages a combination of AI and Raman spectroscopy to provide real-time tissue diagnostics during surgery for otherwise-invisible ...
-
PreludeDx Closes $20 Million in Funding to Advance Growth Initiatives and Development of Its Precision Medicine Portfolio
Prelude Corporation (PreludeDx), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced that it has closed a $20 million funding round led by Evidity Health Capital and joined by existing and new investors including BlueStone Venture Partners. Alejandro Sanchez, Managing Director of Evidity Health Capital, will be joining PreludeDx’s Board of ...
By PreludeDx
-
Alfa Chemistry Newly Introduces Three APIs to Meet Market Demands: Tofacitinib Citrate, Tamoxifen Citrate, and Epalrestat
Alfa Chemistry, a leading pharmaceutical supplier, has recently announced the addition of three new APIs to its full-ranged product catalog, i.e., tofacitinib citrate, tamoxifen citrate, and epalrestat. These new products are introduced to meet the growing demands of the pharmaceutical market. Tofacitinib Citrate Tofacitinib Citrate is a medication used to treat rheumatoid arthritis, psoriatic ...
-
Agilent Technologies Thought Leader Award Supports Dr. Carolyn Mountford, University of Newcastle, Australia
Agilent Technologies Inc. (NYSE: A) today announced that Dr. Carolyn Mountford has received an Agilent Thought Leader Award in recognition of her innovative work using nuclear magnetic resonance (NMR) spectroscopy technology in cancer research. Dr. Mountford is a professor of radiology at The University of Newcastle Australia School of Health Sciences, and Harvard Medical School. She is the ...
-
Bisphenol A exposure can increase risk of diabetes and heart attacks
In human fat tissues, bisphenol A (BPA) suppresses levels of a key hormone, adiponectin, that protects people from heart attacks and Type II diabetes. These results implicate BPA as a potential cause of metabolic syndrome, one of the most serious and costly public health problems in the US. Most Americans have levels of BPA within their serum within the range of concentrations sufficient to ...
-
PreludeDx Presents Compelling DCISionRT Study Results in Young and High-Grade DCIS Patients at ASBrS 2022 Annual Meeting
Prelude Corporation (PreludeDx), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, announced compelling results in 926 women diagnosed with ductal carcinoma in situ (DCIS). The new information was presented in an oral presentation at the American Society of Breast Surgeons (ASBrS) 23rd Annual Meeting, held on April 6 - 10, 2022 at Wynn Las Vegas, NV. The ...
By PreludeDx
-
PreludeDx to Present DCIS Study Results Assessing Benefit of Adjuvant Endocrine Therapy Using DCISionRT During Oral Presentation at ASCO 2022 Annual Meeting
Prelude Corporation (PreludeDx, a leader in molecular diagnostics and precision medicine for early-stage breast cancer, announced today that its study in 926 DCIS patients demonstrating the clinical utility of DCISionRT? was selected for an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting. The results evaluating the association of DCISionRT, a predictive DCIS ...
By PreludeDx
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you